Omega-3 Fish Oil: EPA, DHA Dose & Evidence Review

Quick answer: Omega-3 fatty acids EPA and DHA are the most evidence-backed supplements in existence — with over 40,000 studies and documented effects on cardiovascular mortality (REDUCE-IT: 25% reduction in major cardiovascular events), triglyceride reduction (20–50% dose-dependent), depression (meta-analyses show effect sizes comparable to SSRIs in EPA-dominant formulations), systemic inflammation (hs-CRP reduction), and brain health (DHA constitutes 15–20% of the brain’s dry weight and is required for synapse formation and maintenance). The optimal therapeutic dose is 2–4 g EPA+DHA per day — substantially above the typical supplement dose of 300–600 mg in standard fish oil capsules. Dose and EPA:DHA ratio determine outcomes.

What Omega-3s Actually Are

Omega-3 fatty acids are polyunsaturated fatty acids characterized by a double bond at the third carbon from the omega (methyl) end of the fatty acid chain. The three most clinically relevant omega-3s are:

ALA (alpha-linolenic acid): Found in plant foods (flaxseed, chia, walnuts, hemp). ALA is an essential omega-3 — the body cannot synthesize it from scratch — but it must be converted to EPA and DHA to exert biological activity. The conversion rate is inefficient: typically 5–10% of ALA converts to EPA, and less than 1% to DHA. Plant-based omega-3 sources provide ALA — which is not equivalent to EPA/DHA for clinical purposes.

EPA (eicosapentaenoic acid): Found in fatty fish, fish oil, krill oil, and algal oil. EPA is the primary anti-inflammatory omega-3 — it is the precursor to Series-3 prostaglandins (anti-inflammatory), Series-5 leukotrienes (less pro-inflammatory than Series-4), and resolvins (which actively resolve inflammation). EPA is also the omega-3 form most strongly associated with mood improvement and antidepressant effects — studies using EPA-dominant formulations (EPA:DHA ratio ≥2:1) consistently show stronger antidepressant effects than DHA-dominant formulations.

DHA (docosahexaenoic acid): Also found in fatty fish and algal oil. DHA is the primary structural omega-3 in the brain and retina. It constitutes approximately 15–20% of the brain’s dry weight and is the predominant omega-3 in synaptic membranes, photoreceptors, and sperm. DHA is essential for neuronal membrane fluidity, synaptogenesis, dopamine receptor membrane integrity, and fetal brain development. DHA’s anti-inflammatory properties are primarily via its conversion to neuroprotectin D1 and resolvin D-series, which resolve neuroinflammation.

The Evidence Base: What Omega-3 Actually Does

Cardiovascular: The REDUCE-IT Trial

The 2018 REDUCE-IT trial (NEJM) established high-dose omega-3 as a cardiovascular intervention with hard endpoint reduction. In 8,179 patients with elevated triglycerides already on statins, icosapentaenoic acid (pure EPA, 4 g/day as Vascepa/Lovaza) reduced major adverse cardiovascular events by 25% compared to placebo. This is a substantial outcome effect — comparable to statin therapy itself. The triglyceride-lowering effect of omega-3 is dose-dependent and well-established: 2 g/day reduces triglycerides by approximately 20–30%; 4 g/day reduces them by 30–50% in individuals with elevated baseline levels. Elevated triglycerides are both a cardiovascular risk factor and, importantly for this audience, a driver of leptin resistance by impairing leptin transport across the blood-brain barrier.

Depression and Mood

A 2019 meta-analysis of 26 RCTs (Deane et al., Translational Psychiatry) found omega-3 supplementation significantly improved depressive symptoms with an effect size of 0.36 — comparable to antidepressants — with the strongest effects in EPA-dominant formulations (EPA ≥60% of total omega-3 content, minimum 1 g EPA/day). The mechanism involves multiple pathways: EPA reduces neuroinflammation (via resolvin and neuroprotectin synthesis), DHA supports neuronal membrane fluidity essential for serotonin and dopamine receptor function, and omega-3 reduces cortisol reactivity. A 2014 clinical trial found adding EPA to antidepressant therapy produced superior outcomes to antidepressant alone — confirming the additive effect.

Inflammation: CRP and Cytokines

Omega-3 consistently reduces inflammatory markers in RCTs: hs-CRP reduction of 20–30% with 3–4 g EPA+DHA/day, TNF-α reduction, IL-6 reduction, and NF-κB pathway inhibition. The mechanism is competitive: EPA and DHA compete with arachidonic acid (the pro-inflammatory omega-6) for the same enzymes (COX and LOX), reducing the synthesis of pro-inflammatory Series-2 prostaglandins and Series-4 leukotrienes while increasing anti-inflammatory resolvins. The omega-6:omega-3 ratio in the modern Western diet is approximately 15–20:1; the ancestral ratio was approximately 4:1. This ratio imbalance drives chronic low-grade inflammation across multiple systems. Reducing the ratio to 4:1 (via increasing omega-3 and reducing omega-6 seed oil intake) is an anti-inflammatory dietary intervention with broad systemic effects.

Brain Health and Cognitive Function

DHA’s role in brain structure makes omega-3 uniquely relevant to long-term cognitive health. Several large prospective studies show higher dietary omega-3 intake is associated with slower cognitive decline and reduced Alzheimer’s risk. The mechanism involves DHA’s role in clearing amyloid-beta (via LRP1-mediated transport across the blood-brain barrier), neuroprotectin D1’s anti-apoptotic effect in neurons, and neuroinflammation reduction. Brain fog in adults with low omega-3 status responds to supplementation — the effect is most pronounced in people with documented omega-3 deficiency (erythrocyte DHA below 4%).

Metabolic Health

Omega-3 improves multiple components of metabolic syndrome: triglyceride reduction (most robust effect), modest HDL elevation, VLDL reduction (via reduced hepatic triglyceride synthesis and increased triglyceride clearance), modest blood pressure reduction (3–5 mmHg systolic in hypertensive individuals), and insulin sensitivity improvement via reduction of cellular membrane saturated fat content (replacing with EPA/DHA improves insulin receptor membrane fluidity). The metabolic effects are dose-dependent — the 1 g/day typical supplement is insufficient for these effects; 3–4 g EPA+DHA daily is the therapeutic dose.

The Critical Issue: Dose and Form

Why Most Fish Oil Supplements Are Underdosed

The most common problem with fish oil supplementation is dosing mismatch. A standard fish oil softgel often contains 1,000 mg of fish oil — but only 180 mg EPA and 120 mg DHA (total 300 mg omega-3). To achieve the 2–4 g EPA+DHA therapeutic dose, a person would need to take 7–13 standard capsules daily. The label says “1,000 mg fish oil” — which sounds substantial but delivers only 300 mg of actual omega-3. Reading the supplement label for EPA + DHA milligrams (not “fish oil” milligrams) is essential.

Higher-concentration products (containing 500–900 mg EPA+DHA per capsule) allow achieving therapeutic doses with 3–6 capsules. Prescription omega-3 (Lovaza, Vascepa) provides 4 g EPA+DHA in standardized doses and is covered by insurance when triglycerides exceed 500 mg/dL. Liquid fish oil (1–2 teaspoons/day) is cost-effective and easier to achieve high doses than capsules.

Triglyceride vs. Ethyl Ester vs. Phospholipid Forms

Fish oil omega-3s come in three primary molecular forms with different bioavailability: natural triglyceride (rTG, re-esterified triglyceride) form has the highest bioavailability (approximately 70–90% absorbed), should be taken with food, and most closely resembles the form found in actual fish. Ethyl ester (EE) form (found in most pharmaceutical omega-3 preparations) has lower bioavailability (approximately 20–50%) but higher EPA/DHA concentration; absorption improves dramatically when taken with a high-fat meal. Phospholipid form (found in krill oil) has high bioavailability and contains astaxanthin (an antioxidant), but provides substantially lower omega-3 dose per capsule at much higher cost per gram of EPA+DHA compared to fish oil.

EPA:DHA Ratio for Specific Goals

The EPA:DHA ratio matters for specific therapeutic targets. For mood disorders and depression: EPA-dominant products (EPA:DHA ≥2:1, minimum 1 g EPA/day) — the antidepressant effect is primarily EPA-mediated. For brain health, pregnancy, and infant neurodevelopment: DHA-dominant products — DHA is the structural brain omega-3. For cardiovascular and triglyceride reduction: EPA-only preparations (like Vascepa/icosapentaenoic acid) have stronger REDUCE-IT evidence, but combined EPA+DHA also works. For general anti-inflammatory purposes: Balanced EPA+DHA (1:1 to 2:1 ratio) at 2–4 g/day.

Oxidation: The Fish Oil Quality Problem

Omega-3 fatty acids are highly polyunsaturated — and polyunsaturated fats oxidize. Oxidized fish oil is not merely ineffective; it may be pro-inflammatory and counterproductive. Studies testing commercially available fish oil have found surprisingly high rates of oxidation: a 2015 Consumer Lab analysis found over 50% of tested fish oil supplements exceeded European oxidation limits. Oxidized omega-3 has been shown to blunt the anti-inflammatory effects of fresh omega-3 and to produce lipid peroxide products that are themselves harmful. Quality markers: smell (fresh fish oil should smell mild, not rancid), reputable third-party testing (IFOS certification is the gold standard for omega-3 quality), and freshness date. Products in dark, opaque bottles with antioxidant (vitamin E or astaxanthin) addition have better oxidation resistance. Refrigeration after opening extends freshness.

Omega-3 Testing: The Omega-3 Index

The Omega-3 Index measures EPA+DHA as a percentage of total erythrocyte (red blood cell) fatty acids — reflecting tissue omega-3 status over the preceding 3 months (equivalent to HbA1c for omega-3 status). The target range associated with lowest cardiovascular risk and cognitive protection is 8–12%. The average American Omega-3 Index is approximately 4–5% — in the high-risk range. An index below 4% is strongly associated with increased cardiovascular risk, depression, and cognitive decline. Testing is available through physician ordering (Quest, LabCorp) or direct-to-consumer services. It takes 3–4 months of consistent supplementation to measurably shift the index, and retesting guides dose adjustment.

Plant-Based Omega-3: The ALA Problem

Vegans and vegetarians relying on flaxseed, chia, walnuts, and hemp for omega-3 intake are getting ALA, which requires conversion to EPA and DHA. As noted above, conversion is inefficient (5–10% to EPA, less than 1% to DHA). People with poor delta-6-desaturase activity (common with zinc deficiency, diabetes, or genetic variants) have even lower conversion. The result: plant-based diets without supplementation consistently produce lower Omega-3 Index values and lower DHA levels. Algal oil (the original source of omega-3 in the food chain — fish accumulate EPA/DHA by eating algae) provides EPA and DHA directly and is the recommended solution for plant-based individuals. Algal DHA+EPA (500–1,000 mg EPA+DHA daily) replaces fish-derived omega-3 without animal products.

Safety and Drug Interactions

Omega-3 at doses up to 5 g/day is generally safe, with FDA GRAS status and a long evidence record. The primary concerns: anticoagulant interaction (omega-3 modestly reduces platelet aggregation — at doses above 3 g/day, this may be significant in patients on warfarin, clopidogrel, or aspirin; INR monitoring is advisable in anticoagulated patients). Fishy burp and GI discomfort (minimized by taking with meals, refrigerating, or using enteric-coated products). LDL increase in some individuals (particularly those with familial hypercholesterolemia receiving high-dose DHA — EPA-only preparations avoid this). Bleeding time increase is theoretical at standard doses and not clinically significant except peri-operatively. No serious organ toxicity has been demonstrated at clinical doses in any study population.

The Bottom Line

Omega-3 EPA and DHA are the most evidence-backed supplements available — with hard cardiovascular endpoint reduction, documented antidepressant effects, systemic inflammation reduction, and essential structural roles in brain health. The problem in practice is overwhelmingly underdosing: the 300 mg EPA+DHA in standard fish oil capsules is insufficient for therapeutic effect. The effective dose is 2–4 g EPA+DHA daily (not milligrams of fish oil), from a high-quality, tested, fresh product in a high-concentration formulation, taken with food. Testing the Omega-3 Index before and after supplementation is the most reliable way to confirm adequate tissue incorporation and dose appropriateness. This is one supplement category where quality, dose, and consistency are the entire difference between “no effect” and substantial clinical benefit.

If you are interested in a comprehensive cardiovascular risk assessment including Omega-3 Index, triglycerides, advanced lipid panel, and inflammatory markers — with individualized omega-3 dosing recommendations — call our office at (810) 206-1402 for a functional medicine consultation focused on root-cause cardiovascular and metabolic optimization.

Frequently Asked Questions

How much omega-3 should I take per day?
For general health maintenance: 1–2 g EPA+DHA daily. For therapeutic purposes (depression, triglyceride reduction, cardiovascular risk, significant inflammation): 2–4 g EPA+DHA daily. “EPA+DHA” refers to the combined active omega-3 content — not the total “fish oil” milligrams on the label, which includes inert fats. To achieve 3 g EPA+DHA, most people need 8–10 standard softgels (300 mg EPA+DHA each) or 3–4 high-concentration capsules (800–900 mg EPA+DHA each).

Is fish oil the same as omega-3?
Fish oil is a source of omega-3, not synonymous with it. Fish oil is the oil extracted from fatty fish tissue; it contains EPA and DHA as the active omega-3 components, plus other fats. Other omega-3 sources include krill oil (phospholipid form, lower dose, higher cost), algal oil (plant-based EPA+DHA, the direct source that fish themselves use), and cod liver oil (contains EPA/DHA plus vitamins A and D). “Omega-3” as a supplement category refers specifically to EPA and DHA content — the label milligrams of EPA+DHA, not total product weight.

What are the signs of omega-3 deficiency?
There is no single biomarker universally accepted as an omega-3 deficiency marker, but the Omega-3 Index (erythrocyte EPA+DHA percentage) below 4% indicates deficiency. Clinical signs associated with low omega-3 status: dry, rough, or itchy skin (omega-3 maintains skin barrier lipids), brittle hair and nails, poor concentration and memory difficulties, joint pain and stiffness (omega-3 modulates joint inflammation), low mood and difficulty with emotional regulation, and elevated triglycerides. These signs are non-specific but together with a low dietary intake of fatty fish suggest omega-3 deficiency.

Can omega-3 cause side effects?
At standard doses (up to 3–4 g EPA+DHA daily), omega-3 is well-tolerated. The most common side effect is fishy burp and GI discomfort — minimized by refrigerating capsules, taking with meals, or using enteric-coated products. Higher doses (above 5 g/day) may modestly prolong bleeding time, which is relevant for patients on anticoagulant medications. A modest LDL increase has been observed with high-dose DHA in some individuals with genetic lipid conditions. No organ toxicity has been demonstrated at clinical doses.

Omega-3 EPA and DHA: The Evidence, the Dose, and Why Most Fish Oil Fails